← All trials
NCT00109161
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2005
- Primary completion
- —
- Completion date
- Oct 1, 2006
- First posted
- —
- Last posted
- —
- Enrollment
- 270
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- PDL BioPharmaLead sponsor
- University of CalgaryOverall official - principal investigator
- University of RochesterOverall official - principal investigator
- University of PennsylvaniaOverall official - principal investigator
- Michigan State UniversityOverall official - principal investigator
- University of AlbertaOverall official - principal investigator
- Albany Medical CollegeOverall official - principal investigator
- Mayo ClinicOverall official - principal investigator
- University of CincinnatiOverall official - principal investigator
- University of ArizonaOverall official - principal investigator
- Wenatchee Valley Medical CenterOverall official - principal investigator
- Rockwood Clinic, PSOverall official - principal investigator
- Sutter East Bay Medical FoundationOverall official - principal investigator
- Upstate Clinical ResearchOverall official - principal investigator
- Michigan Medical P.C. NeurologyOverall official - principal investigator
- MS Hub Medical GroupOverall official - principal investigator
- Raleigh Neurology AssociatesOverall official - principal investigator
- The Multiple Sclerosis Center of AtlantaOverall official - principal investigator
- Maryland Center for MSOverall official - principal investigator
- Texas NeurologyOverall official - principal investigator
- University of UtahOverall official - principal investigator
- Wayne State UniversityOverall official - principal investigator
- Dartmouth UniversityOverall official - principal investigator
- McGill UniversityOverall official - principal investigator
- Central Texas Neurology ConsultantsOverall official - principal investigator
- St. Louis UniversityOverall official - principal investigator
- University of Western OntarioOverall official - principal investigator
- Winthrop UniversityOverall official - principal investigator
- Louisiana State UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.